Anthem Biosciences Ltd IPO

Anthem Biosciences Ltd IPO

Pharmaceuticals

mainboard

Bidding period

14 Jul 2025 - 16 Jul 2025

Bid price

₹570.00 - ₹570.00

Listing on

BSE, NSE

Listing date

21 Jul 2025

Lot size

26 shares

Issue size

₹3,395.00 crore


Minimum investment

₹14,820.00 / 1 lot

Maximum investment

₹1,92,660.00 / 13 lot

Bidding closed on 16 Jul 2025

EXPLORE IPOs
EXPLORE IPOs

Anthem Biosciences Ltd IPO dates

IPO opening date

14 Jul 2025

IPO end date

16 Jul 2025

Allotment date

17 Jul 2025

Initiation of refunds

18 Jul 2025

Credit of shares to demat

18 Jul 2025

IPO listing date

21 Jul 2025

Anthem Biosciences Ltd IPO financials

Particulars

For the period ending in March 2024 (in ₹ million)

Total assets ₹2,324.23
Total liabilities ₹2,324.23
Total expenditure ₹1,003.29
Total revenue ₹1,488.06
Profit after tax ₹374.78
EBITDA ₹575.41
Adjusted EBITDA ₹0.00

Anthem Biosciences Ltd shareholder pattern

Pre-issue Post-issue
Promoter group 76.87 74.69
Public group 23.13 25.31

Anthem Biosciences Ltd strengths and risks

Information currently unavailable

  • The Company offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.

  • Its innovation-focused approach has enabled it to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.

  • Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products,

  • Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.

  • Its business depends on the demand for the company CRDMO services, which contributed to 81.65% of its revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they operate may have a material adverse effect on the company business.

  • Developmental and commercial manufacturing contributed to 70.78% of its revenue from operations and 71.90% of the company total number of Projects in Fiscal 2025. Its business may be adversely affected by a failures in early phase developmental Projects or a failures to develop or manufacture commercially viable drugs, including for reasons that are not within its control.

  • Its financial performance is dependent on the success of the molecules the company manufacture, and its revenue from operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failures of a phase III molecule and withdrawal of a commercialized molecule. Accordingly, any unfavorable developments affecting these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of commercialized molecules, may have an adverse impact on its business, financial condition, results of operations and prospects.

  • The company is subject to rapid advancements in technology which requires continuous investments. Its may not be successful in developing new technologies and improving its existing technologies to maintain the company competitive position. Any such failures to develop technologies may have a material and adverse impact on its business, financial condition and results of operations.

  • The company is subject to extensive government regulations, and if its fail to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate the company business, results of operations and cash flows may be adversely affected.

  • The company depends on certain key customers for a significant portion of its revenues (its top 5 and top 10 customers contributed to 70.92% and 77.33%, respectively, of its revenue from operations in Fiscal 2025). Any inability to retain the company key customers or decrease in revenues from any of its key customers could negatively affect the company business and results of operations.

  • The company is dependent on its arrangements with DavosPharma, the affiliate of one of its Shareholders and also a Selling Shareholder, for the company business and marketing activities in the United States.

  • The company faces the risk of losing manufacturing revenue from services supplied to innovator pharmaceutical companies after the expiry of their patent protection period, which may lead to the availability of alternative formulations at a lower cost.

  • The company is highly dependent on its skilled workforce, in particular its R&D team, for the company day-to-day operations. The loss of, or its inability to attract or retain such persons may lead to knowledge loss and have a material adverse effect on the company business performance.

  • The Offer Price of its Equity Shares, the company price-to-earnings ratio, its enterprise value to EBITDA ratio and the company market capitalisation to total revenue from operations ratio may not be indicative of the trading price of its Equity Shares upon listing on the Stock Exchanges subsequent to the Offer and, as a result, you may lose a significant part or all of your investment.

How to check the allotment status of the Anthem Biosciences Ltd IPO?

To check the IPO allotment status, follow these steps:

 

  1. Visit the official website of the IPO’s registrar.
  2. Go to the IPO allotment status page.
  3. Select the ‘Anthem Biosciences Ltd’ from the list of available IPOs.
  4. Enter your PAN, Demat ID, or application number.
  5. Click on ‘Submit’ or ‘Check Status’ to view your allotment details.

Alternatively, you can also check the allotment status on stock exchange websites such as the NSE or BSE.

Read more Read less

Anthem Biosciences Ltd IPO registrar

KFin Techologies Ltd

Phone number +91 40 6716 2222
E-mail ID einward.ris@kfintech.com
Website www.kfintech.com

Anthem Biosciences Ltd IPO reservation

QIB shares offered

1,18,83,334 (19.95%)

NII (HNI) shares offered

89,12,500 (14.96%)

Retail shares offered

2,07,95,832 (34.91%)

Anchor investor shares offered

1,78,25,000 (29.93%)

Total shares offered

5,95,61,404

Total shares with anchor investor

5,95,61,404

Anthem Biosciences Ltd IPO lead manager

  • JM Financial Ltd
  • Citigroup Global Markets India Pvt Ltd
  • J.P.Mprgan India Pvt Ltd
  • Nomura Financial Advisors & Securities (India) P

Explore other IPOs

Indiqube Space Limited logo
Indiqube Space Limited logo

Indiqube Space Limited IPO

Bidding period

23 Jul 2025 - 25 Jul 2025

Bid price range

₹225.00 - ₹237.00
Indiqube Spaces Limited logo
Indiqube Spaces Limited logo

Indiqube Spaces Limited IPO

Bidding period

23 Jul 2025 - 25 Jul 2025

Bid price range

₹225.00 - ₹237.00
GNG Electronics Limited logo
GNG Electronics Limited logo

GNG Electronics Limited IPO

Bidding period

23 Jul 2025 - 25 Jul 2025

Bid price range

₹225.00 - ₹237.00
Brigade Hotel Ventures Limited logo
Brigade Hotel Ventures Limited logo

Brigade Hotel Ventures Limited IPO

Starts tomorrow
Starts tomorrow

Bidding period

24 Jul 2025 - 28 Jul 2025

Bid price range

₹85.00 - ₹90.00
Shanti Gold International Limited logo
Shanti Gold International Limited logo

Shanti Gold International Limited IPO

Bidding period

25 Jul 2025 - 29 Jul 2025

Bid price range

₹189.00 - ₹199.00
Aditya Infotech Limited logo
Aditya Infotech Limited logo

Aditya Infotech Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Advance Agrolife Limited logo
Advance Agrolife Limited logo

Advance Agrolife Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Advanced SysTek Limited logo
Advanced SysTek Limited logo

Advanced SysTek Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Aggcon Equipments International Limited logo
Aggcon Equipments International Limited logo

Aggcon Equipments International Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Agilus Diagnostics Limited logo
Agilus Diagnostics Limited logo

Agilus Diagnostics Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Airox Technologies Limited logo
Airox Technologies Limited logo

Airox Technologies Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Ajay Poly Limited logo
Ajay Poly Limited logo

Ajay Poly Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
All Time Plastics Limited logo
All Time Plastics Limited logo

All Time Plastics Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Allchem Lifescience Limited logo
Allchem Lifescience Limited logo

Allchem Lifescience Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Allied Engineering Works Limited logo
Allied Engineering Works Limited logo

Allied Engineering Works Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced
Amanta Healthcare Limited logo
Amanta Healthcare Limited logo

Amanta Healthcare Limited IPO

Bidding period

To Be Announced

Bid price range

To Be Announced

How to apply for an IPO with Bajaj Broking?

adafafds
 
 
  • Log in to the Bajaj Broking trading platform and select ‘IPO’ from the menu.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen IPO.
  • Enter the quantity and your UPI ID.
  • Submit your application—and you're done!

Frequently asked questions

What is the listing date for the Anthem Biosciences Ltd IPO?

The listing date for the Anthem Biosciences Ltd IPO is 21 Jul 2025.

What is the issue size of Anthem Biosciences Ltd IPO?

The issue size of the Anthem Biosciences Ltd IPO is ₹3,395.00 cr.

What is the minimum lot size needed for Anthem Biosciences Ltd IPO?

The minimum lot size for Anthem Biosciences Ltd IPO is 26

When does the Anthem Biosciences Ltd open and close?

Anthem Biosciences Ltd IPO is open from 14 Jul 2025 to 16 Jul 2025.

How can I apply for the Anthem Biosciences Ltd IPO?

To apply for the Anthem Biosciences Ltd, follow the steps given below:

  • Log in to your Bajaj Broking trading account and navigate to the current IPOs section.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen PO.
  • Enter the quantity and your UPI ID. You will receive a mandate notification to block funds in your UPI app.
SHOW MORE SHOW LESS

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."

**Disclaimer: For Bajaj Financial Securities Limited

Investments in securities market are subject to market risk, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. All leveraged intraday positions will be squared off the same day. There is no restriction on withdrawal of unutilised margin amount. Trade Recommendations are research-calls provided under the SEBI Research Analyst guidelines.
Visit https://www.bajajbroking.in/disclaimer for complete disclaimer.

Securities market Products/services are made available only at the discretion of BFSL and subject to the individual contractual terms and conditions of the respective Securities market products/services. You shall be the sole owner of any decision to invest in any BFSL's Securities market products/services.

Securities market products/services may be withdrawn or amended at any time by BFSL without notice and your recourse in such case would be directly to reach out BFSL at connect@bajajfinserv.in or 1800 833 8888.

Powered by Bajaj Financial Securities Limited (Bajaj Broking)